Skip to content

Remineralisation of White Spot Lesions by Elmex® gelée in Post-orthodontic Patients

White Spot Lesion Development in Post-orthodontic Patients Following Weekly Application of a 1.25% Fluoride Gel Compared to Placebo Over 6 Months

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01329731
Enrollment
48
Registered
2011-04-06
Start date
2011-03-31
Completion date
2013-10-31
Last updated
2013-12-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Tooth; Lesion, White Spot Lesions

Keywords

white spot lesion, initial caries, fluoride, amine fluoride, orthodontics, remineralization, brackets

Brief summary

The aim of this study is to monitor the effect of intraoral topical high fluoride application on the development of white spot lesions (WSL) after orthodontic treatment with multibracket appliances and to compare it to a placebo.

Interventions

DRUGelmex® gelée

1.25% fluoride (elmex® gelée) Dosage: Weekly brushing with 0.5g of respective gel Route: Intraoral topical

DRUGnegative control (placebo)

0% fluoride (negative control) Dosage: Weekly brushing with 0.5g Route: Intraoral topical

Sponsors

PD Dr. Christian Heumann
CollaboratorUNKNOWN
Gaba International AG
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
ALL
Age
11 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Written informed consent * Healthy volunteers (≥11 years) scheduled for bracket removal * ≥ 1 WSL with a modified score 1 or 2 (Gorelick et al. 1982) on UFT at debonding

Exclusion criteria

* Known hypersensitivity or allergy to study products and standard toothpaste ingredients and/or dental material used in the present study * Known hypersensitivity or allergy to placebo gel ingredients * Alterations in the teeth's enamel, e.g. hypoplasia, fluorosis * Any illness/condition potentially affecting the study outcome at investigator's discretion * Known pregnancy or breast feeding during the course of the study

Design outcomes

Primary

MeasureTime frameDescription
WSL-size change12 weeksChanges in size of white spot lesions (WSL) at 12 weeks

Secondary

MeasureTime frameDescription
WSL-brightness changeBaseline up to 24 weeksChanges in WSL brightness value (%)
WSL index on all upper front teethBaseline up to 24 weeksModified white spot lesion index (Gorelick et al. 1982): 0: no white spot formation 1. slight white spot formation, thin rim 2. excessive white spot formation, thicker bands 3. white spot formation with cavitation
Caries activityBaseline up to 24 weeksCaries activity index (LAA) according to the ICDAS II (Ekstrand et al. 2007)
WSL-size changeBaseline up to 24 weeksChanges in size of WSL over study time
Gingival bleeding index on all upper front teethBaseline up to 24 weeksGingival bleeding index (Ainamo and Bay 1975). The following scores will be used: (0) no bleeding (1) bleeding occurs
DMFT index: Dental health of all teethBaseline, 24 weeksDMFT index according to Klein et al. (1938): Dental health of all teeth will be assessed with respect to decay (D), missing (M) or filling (F). The DMFT-Index will be calculated.
Plaque index (Silness and Löe 1964)on all upper front teethBaseline up to 24 weeksThe grades will be assessed visually on all upper front teeth using a standard dental probe. (0) no plaque on inspection and probing 1. thin plaque film on gingival margin, detectable only on probing 2. moderate plaque film along the gingival margin, visually detectable even without probing 3. a lot of plaque along the gingival margin, filling the interdental spaces

Countries

Germany

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 10, 2026